Lavelle Capital LP Purchases Shares of 30,000 Pfizer Inc. $PFE

Lavelle Capital LP acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $842,000.

Several other large investors have also recently made changes to their positions in the company. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the period. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at about $26,000. YANKCOM Partnership acquired a new position in Pfizer in the 4th quarter worth about $28,000. HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC increased its position in shares of Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 650 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.8%

Shares of NYSE:PFE opened at $25.10 on Friday. The company has a market capitalization of $143.06 billion, a price-to-earnings ratio of 19.16 and a beta of 0.35. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The business has a 50-day moving average price of $25.04 and a 200 day moving average price of $26.15. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the firm posted $0.92 earnings per share. Pfizer’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s payout ratio is presently 131.30%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wolfe Research reissued an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. UBS Group reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.50.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 vitiligo data: Pfizer reported that oral LITFULO significantly improved skin repigmentation in two late-stage trials for nonsegmental vitiligo. The results support planned regulatory filings and could create a new growth opportunity for the company. Reuters LITFULO vitiligo trial article
• Positive Sentiment: Updated COVID vaccine approved in Europe: The European Commission authorized Pfizer and BioNTech’s XFG-adapted vaccine for the 2026–2027 season across the European Union. The approval enables production and advance supply, although seasonal COVID demand remains difficult to forecast. EU approval article
• Positive Sentiment: Value appeal and estimates: Investor commentary highlights Pfizer’s roughly 6.8% dividend yield and inexpensive earnings valuation, while Erste Group reportedly raised its FY2027 EPS estimate. These factors may attract income and value-focused investors. Pfizer valuation article
• Neutral Sentiment: Upcoming earnings focus: Analysts are watching Pfizer’s second-quarter revenue, adjusted earnings, product sales and full-year outlook. The available reports are previews rather than an announcement of actual quarterly results, so earnings remain a near-term catalyst. Pfizer Q2 earnings preview
• Negative Sentiment: Growth concerns remain: Pfizer’s valuation reflects investor skepticism about post-pandemic revenue, a comparatively modest growth profile and execution risks surrounding its pipeline. Its obesity-drug candidate is promising but still late-stage and faces powerful competition from Eli Lilly and Novo Nordisk, limiting any immediate earnings benefit. Pfizer earnings preview and valuation article

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.